Pipeline activity
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Pressure score
71
Momentum score
21
Why This Matters
Lilly is a direct competitive threat because it has a Phase II program in Neurology · Alzheimer's Disease (Pipeline activity) and could narrow Merck's development lead — particularly against Alzheimer.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Phase II
- Stage gap
- Competitor is at a comparable development stage, indicating head-to-head race dynamics.
- Market share risk
- Moderate share risk if competitor advances before the signal sponsor establishes label leadership.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Alzheimer is named in this signal's competitive context as a direct competitor to the signal asset in Neurology · Alzheimer's Disease.
Source: Lilly
View source documentRelated Signal
Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #2 of 2
Roche
4 competitive findings
Top program: Pipeline activity
- Pressure
- 91
- Momentum
- 51
- Threat
- regulatory competitor
- Stage
- Approved
91RocheCriticalPipeline activity·Approved
Lilly
1 competitive finding
Top program: Pipeline activity
- Pressure
- 71
- Momentum
- 21
- Threat
- direct competitor
- Stage
- Phase II
71LillyHighPipeline activity·Phase II